Clinical TrialHighlightedHydrogen’s Feasibility and Safety as a Therapy in Extracorporeal Cardiopulmonary Resuscitation (Hydrogen‑FAST): study protocol for a trial of inhaled hydrogen gas as an adjunctive therapy in refractory cardiac arrestMHID-5491717PMID: 412043202025TrialsVictoria Habet, Tysen DeWaard, Krislyn M. Boggs, Alix Fetch, Bao Nguyen Puente, Lynn A. Sleeper, et al.Background: Extracorporeal cardiopulmonary resuscitation (ECPR) improves survival for patients experiencing refractory cardiac arrest but is often associated with severe ischemia-reperfusion injury (IRI). Hydrogen gas (H2) has demonstrated promising preclinical efficacy in reducing IRI. The Hydrogen-FAST trial investigates the feasibility and safety of inhaled hydrogen gas as an adjunctive therapy
Clinical TrialHighlightedHydrogen-rich water alleviates inflammation and fatigue in COVID-19: A pilot studyMHID-50217702022European Journal of InflammationAleksandra Milovancev, Jovana Avakumovic, Patrik Drid, Nikola Todorovic, Valdemar Stajer, Sergej M OstojicMolecular hydrogen (H2) has been recently put forward as a possible adjunct therapeutics in COVID-19 due to its anti-inflammatory and pulmo-protective effects.1,2 An open-label randomized trial in 44 patients with laboratory-confirmed COVID-19 from seven hospitals in China demonstrated that 3-day hydrogen inhalation resulted in significantly more patients with improved disease severity and reduced dy
